Transplacental Transport of Artificial Sweeteners
Nutrients · 2023
DOI: 10.3390/nu15092063 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2023. Verfasst von Magnus Leth-Møller und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200 Aarhus Nord, Denmark. Hauptthemen laut MEDLINE: Sweetening Agents, Saccharin. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: P. Carl Petersen Foundation, Helga and Peter Korning Foundation, A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond.
Abstract (Originalsprache)
The prevalence of obesity is increasing, and the origins of obesity and metabolic dysfunction may be traced back to fetal life. Currently, overweight pregnant women are advised to substitute sugar-sweetened beverages with diet drinks containing artificial sweeteners. Recent evidence suggests that the consumption of artificial sweeteners during pregnancy increases the risk of obesity in the child, but the mechanism is unknown. We hypothesized the transportation of artificial sweeteners across the placenta into the fetal circulation and the amniotic fluid. We included 19 pregnant women who were given an oral dose of acesulfame, cyclamate, saccharin, and sucralose immediately before a planned caesarean section. Nine women were included as controls, and they refrained from an intake of artificial sweeteners. The maternal and fetal blood and amniotic fluid were collected during the caesarean section, and concentrations of artificial sweeteners were measured using mass spectrometry. We found a linear relationship between the fetal plasma concentrations of artificial sweeteners and the maternal plasma concentrations, with adjusted coefficients of 0.49 (95% CI: 0.28–0.70) for acesulfame, 0.72 (95% CI: 0.48–0.95) for cyclamate, 0.51 (95% CI: 0.38–0.67) for saccharin, and 0.44 (95% CI: 0.33–0.55) for sucralose. We found no linear relationship between amniotic fluid and fetal plasma concentrations, but there were positive ratios for all four sweeteners. In conclusion, the four sweeteners investigated all crossed the placenta and were present in the fetal circulation and amniotic fluid.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200 Aarhus Nord, Denmark.
- Comparative Medicine Lab, Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulevard 11, 8200 Aarhus Nord, Denmark.
- Department of Clinical Medicine, Health, Aarhus University, Palle Juul-Jensens Boulevard 99, 8200 Aarhus Nord, Denmark.
- Department of Clinical Biochemistry, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200 Aarhus Nord, Denmark.
- Steno Diabetes Center Aarhus, Aarhus University Hospital, Palle Juul-Jensens Boulevard 11, 8200 Aarhus Nord, Denmark.
ORCID-Profile: Magnus Leth-Møller, Christina Søndergaard Duvald, Elke Hoffmann-Lücke
Förderung
- P. Carl Petersen Foundation
- Helga and Peter Korning Foundation
- A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond
- P. Carl Petersens Foundation
- A.P. Møller and Chastine Mc-Kinney Møller Foundation
Zitieren
APA
Leth-Møller, M., Duvald, C. S., Stampe, S., Greibe, E., Hoffmann-Lücke, E., Pedersen, M., & Ovesen, P. G. (2023). Transplacental Transport of Artificial Sweeteners. Nutrients. https://doi.org/10.3390/nu15092063
Vancouver
Leth-Møller M, Duvald CS, Stampe S, Greibe E, Hoffmann-Lücke E, Pedersen M, et al. Transplacental Transport of Artificial Sweeteners. Nutrients. 2023. doi:10.3390/nu15092063
BibTeX
@article{LethMller2023,
author = {Leth-Møller, Magnus and Duvald, Christina Søndergaard and Stampe, Sofie and Greibe, Eva and Hoffmann-Lücke, Elke and Pedersen, Michael and Ovesen, Per Glud},
title = {Transplacental Transport of Artificial Sweeteners},
journal = {Nutrients},
year = {2023},
doi = {10.3390/nu15092063}
}
EUVIMED